THYROID EYE DISEASE
Clinical trials for THYROID EYE DISEASE explained in plain language.
Never miss a new study
Get alerted when new THYROID EYE DISEASE trials appear
Sign up with your email to follow new studies for THYROID EYE DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Second chance: new drug tested for stubborn thyroid eye disease
Disease control Recruiting nowThis study tests a drug called AMG 732 in 30 adults with thyroid eye disease who either did not respond to treatment or saw their symptoms return after a previous study. The main goal is to see if the drug can reduce eye bulging by at least 2 millimeters without worsening the oth…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug AMG 732 aims to reduce eye bulging in thyroid eye disease
Disease control Recruiting nowThis study tests a new drug called AMG 732 for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. The trial has two parts: Part A checks safety in healthy volunteers, and Part B tests how well the drug works in patients.…
Matched conditions: THYROID EYE DISEASE
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug and high-tech scans aim to calm thyroid eye disease
Disease control Recruiting nowThis study tests a drug called teprotumumab N01 in 50 adults with thyroid eye disease, an autoimmune condition that causes bulging eyes and discomfort. Participants receive the drug and are monitored with special PET and MRI scans to see if inflammation and eye changes improve. T…
Matched conditions: THYROID EYE DISEASE
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug aims to reduce bulging eyes in thyroid disease
Disease control Recruiting nowThis Phase 3 trial tests IBI311 (teprotumumab) in 111 people with inactive thyroid eye disease. The main goal is to see if the drug can reduce eye bulging by at least 2 mm after 24 weeks. Participants receive either the drug or a placebo, and the study lasts up to 64 weeks.
Matched conditions: THYROID EYE DISEASE
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Scientists track prednisolone levels to improve dosing for inflammatory conditions
Knowledge-focused Recruiting nowThis pilot study is measuring prednisolone levels in 120 people with inflammatory diseases like thyroid eye disease, vasculitis, COPD, asthma, and others. Participants take high-dose prednisolone as part of their routine care, and researchers take timed blood samples to see how t…
Matched conditions: THYROID EYE DISEASE
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC